Eloquent efficacy for Eliquis in atrial fibrillation patients

Preliminary results from the International Society on Thrombosis and Haemostasis (ISTH) meeting and the ARISTOTLE study show that a comparison of Eliquis (apixiban) to an older blood thinner called warfarin (Coumadin) revealed that the new drug (Xa inhibitor) is non-inferior in preventing stroke and systemic blood clots (emboli).

The important thing is that ARISTOTLE is a very large study with more than 18,000 atrial fibrillation (more likely to have abnormal blood clots) from 1,000 sites in about 40 countries. People in the study were given either warfarin or apixiban twice a day. The new medicine will have the brand name Eliquis and the full results of the study will be released at the European Society of Cardiology meeting in Paris on August 28th.

While Eliquis is still experimental, if it gains approval, it would compete with dabigatran (Pradaxa) and rivaroxiban (Xarelto) for this approval. Additional momentum for Eliquis was realized from the AVERROES study (5,599 people with atrial fibrillation who could not take warfarin). Apixiban is actually approved currently in Europe (27 countries of the EU) where it is used to prevent blood clots (VTE or venous thromboembolic events) in adults who have had knee replacement or hip surgery.

Contact Us